- Home
- AEON vs PASG Comparison
AEON vs PASG Comparison
Compare AEON & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | PASG |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 14.8M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AEON | PASG |
|---|---|---|
| Price | $0.19 | $4.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.20 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 981.2K | 15.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $3.29 |
| 52 Week High | $1.45 | $20.00 |
Technical Indicators
Market Signals| Indicator | AEON | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 20.40 | 42.52 |
| Support Level | N/A | $4.25 |
| Resistance Level | $0.34 | $4.94 |
| Average True Range (ATR) | 0.03 | 0.29 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 13.31 | 29.17 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.